HolderBook

NASUS PHARMA LTD (NSRX)

Institutional ownership reported to the SEC as of Q2 2026, across 4 quarters.

10
Reporting holders
$7.5M
Reported value
23.9%
Of shares outstanding
0.0%
Held as options
+2
Holder change

Institutions report 2,150,411 shares against 9,015,383 outstanding. Shares only - option lines are excluded, which is why this can be compared with the company at all. The count comes from the cover page of the company's own most recent report, so it is dated when that was filed rather than at quarter end. Share count carried from an earlier filing (cy2025q4i).

Options share is the part of reported value carried in derivative lines rather than shares. A high figure means institutions are expressing a view on this security without owning much of it.

Holders

FilerValueShares Their book Held Change
Balyasny Asset Management L.P.$3.1M898,4730.00%2qHELD
Cable Car Capital, LP$2.2M616,0810.05%2q+2.3%+$49.3K
Velan Capital Investment Management LP$1.3M359,3900.77%2qHELD
Hudson Bay Capital Management LP$471.7K134,7710.00%2qHELD
Bleichroeder LP$314.5K89,8480.06%2qHELD
CITADEL ADVISORS LLC$77.0K22,0040.00%newNEW
XTX Topco Ltd$58.2K16,6400.00%newNEW
RENAISSANCE TECHNOLOGIES LLC$42.7K12,2000.00%newNEW
MORGAN STANLEY$3.5K1,0000.00%4q-50.0%-$3.5K
Caitong International Asset Management Co., Ltd$1440.00%newNEW

Five percent filings

Anyone crossing 5% of a company must say so within days - far sooner than the next quarterly holdings report. A 13D declares an intent to influence the company; a 13G is the passive version. See all activist filings →

FiledFormFiler % of class
2026-08-1413G/ABALYASNY ASSET MANAGEMENT L.P.with 4 co-filers10.0%

Quarter by quarter

Coverage begins with the quarter ending 2018-12-31. Earlier filings exist only as occasional late amendments, too sparse to describe a market, so they are not shown.

QuarterHoldersValue SharesNewAdded TrimmedOptions
Q2 202610$7.5M2,150,4114110.0%
Q1 20268$4.7M2,135,3776100.0%
Q4 20252$21.8K2,3780010.0%
Q3 20252$21.6K3,2412000.0%